Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
![]() |
Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumoursRomer, A. ; Seiler, D. ; Marincek, N. ; Brunner, P. ; Koller, M. T. ; Ng, Q. K. T. ; Maecke, H. R. ; Müller-Brand, J. ; Rochlitz, C. ; Briel, M. ; Schindler, C. ; Walter, M. A.European journal of nuclear medicine and molecular imaging, 2014-02, Vol.41 (2), p.214-222 [Periódico revisado por pares]Berlin/Heidelberg: Springer Berlin HeidelbergTexto completo disponível |
2 |
Material Type: Artigo
|
![]() |
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation studyMarincek, Nicolas ; Jörg, Ann-Catherine ; Brunner, Philippe ; Schindler, Christian ; Koller, Michael T ; Rochlitz, Christoph ; Müller-Brand, Jan ; Maecke, Helmut R ; Briel, Matthias ; Walter, Martin AJournal of translational medicine, 2013-01, Vol.11 (1), p.17-17, Article 17 [Periódico revisado por pares]England: BioMed Central LtdTexto completo disponível |
3 |
Material Type: Artigo
|
![]() |
Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine CancersVILLARD, Linda ; ROMER, Anna ; BRIEL, Matthias ; WALTER, Martin A ; MARINCEK, Nicolas ; BRUNNER, Philippe ; KOLLER, Michael T ; SCHINDLER, Christian ; NG, Quinn KT ; MÄCKE, Helmut R ; MÜLLER-BRAND, Jan ; ROCHLITZ, ChristophJournal of clinical oncology, 2012-04, Vol.30 (10), p.1100-1106 [Periódico revisado por pares]Alexandria, VA: American Society of Clinical OncologyTexto completo disponível |
4 |
Material Type: Artigo
|
![]() |
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine CancersIMHOF, Anna ; BRUNNER, Philippe ; MARINCEK, Nicolas ; BRIEL, Matthias ; SCHINDLER, Christian ; RASCH, Helmut ; MÄCKE, Helmut R ; ROCHLITZ, Christoph ; MÜLLER-BRAND, Jan ; WALTER, Martin AJournal of clinical oncology, 2011-06, Vol.29 (17), p.2416-2423 [Periódico revisado por pares]Alexandria, VA: American Society of Clinical OncologyTexto completo disponível |
5 |
Material Type: Artigo
|
![]() |
The German ACROSTUDY: past and presentBuchfelder, M ; Schlaffer, S ; Droste, M ; Mann, K ; Saller, B ; Brübach, K ; Stalla, G K ; Strasburger, C JEuropean journal of endocrinology, 2009-11, Vol.161 (suppl_1), p.S3-S10 [Periódico revisado por pares]England: BioScientificaTexto completo disponível |
6 |
Material Type: Artigo
|
![]() |
Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational StudyBuchfelder, M ; Weigel, D ; Droste, M ; Mann, K ; Saller, B ; Brübach, K ; Stalla, G K ; Bidlingmaier, M ; Strasburger, C JEuropean journal of endocrinology, 2009-07, Vol.161 (1), p.27-35 [Periódico revisado por pares]Bristol: BioScientificaTexto completo disponível |
7 |
Material Type: Artigo
|
![]() |
[90Yttrium-DOTA]-TOC Response Is Associated With Survival Benefit in Iodine-Refractory Thyroid Cancer : Long-term Results of a Phase 2 Clinical TrialITEN, Fabienne ; MULLER, Beat ; SCHINDLER, Christian ; RASCH, Helmut ; ROCHLITZ, Christoph ; OERTLI, Daniel ; MAECKE, Helmut R ; MULLER-BRAND, Jan ; WALTER, Martin ACancer, 2009-05, Vol.115 (10), p.2052-2062 [Periódico revisado por pares]Hoboken, NJ: Wiley-BlackwellTexto completo disponível |
8 |
Material Type: Artigo
|
![]() |
Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical TrialITEN, Fabienne ; MÜLLER, Beat ; SCHINDLER, Christian ; ROCHLITZ, Christoph ; OERTLI, Daniel ; MÄCKE, Helmut R ; MÄLLER-BRAND, Jan ; WALTER, Martin AClinical cancer research, 2007-11, Vol.13 (22), p.6696-6702 [Periódico revisado por pares]Philadelphia, PA: American Association for Cancer ResearchTexto completo disponível |
9 |
Material Type: Artigo
|
![]() |
An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate CancerSalzberg, Marc ; Rochlitz, Christoph ; Morant, Rudolf ; Thalmann, George ; Pedrazzini, Augusto ; Roggero, Enrico ; Schönenberger, Astrid ; Knuth, Alexander ; Borner, MarkusOncology research and treatment, 2007-07, Vol.30 (7), p.355-360 [Periódico revisado por pares]Freiburg, GermanyTexto completo disponível |
10 |
Material Type: Artigo
|
![]() |
A case of post‐transplant lymphoproliferative disease presenting as CD20‐expressing, Epstein–Barr‐virus positive Hodgkin lymphomaStern, M. ; Herrmann, R. ; Rochlitz, C. ; Dirnhofer, S. ; Pless, M.European journal of haematology, 2005-03, Vol.74 (3), p.267-270 [Periódico revisado por pares]Oxford, UK: Munksgaard International PublishersTexto completo disponível |